Global Alliance for Vaccine & Immunization GAVI Raised US$ 66 Million

January 30, 2010 By Robert Graham ---- Phacilitate’s 7th annual Cell & Gene Therapy Forum in Washington DC


While Attending Phacilitate’s 7th annual Cell & Gene Therapy Forum in Washington DC Hybrid Medical Media came up with the New Slogan for Global Alliance for Vaccine & Immunization (GAVI) "Committed to Our Mission with Analytics" Soon After

Bill Gates and ABU DHABI, UNITED ARAB EMIRATES on - January 25, 2011: HH General Sheikh Mohammed bin Zayed Al Nahyan Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces (right) receives Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation, at the Al Bateen Palace. (Philip Cheung / Crown Prince Court - Abu Dhabi).
US$ 66 million donation from the Crown Prince of Abu Dhabi and the Bill & Melinda Gates Foundation for children in Afghanistan

Geneva, 26 January 2011 — A new partnership marking broader global collaboration around vaccines injects needed funding into the GAVI Alliance’s efforts to help save millions of children and hopefully inspires other philanthropists to invest in childhood immunisation programmes.
Private donations like this send a clear signal to our government donors that they are not alone in seeing the value of immunisation.
Dagfinn Høybråten, Chair of the GAVI Alliance board

Announced in Abu Dhabi on Wednesday, His Highness Sheikh Mohamed bin Zayed Al Nahyan, the Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, and the Bill & Melinda Gates Foundation entered into a partnership in which each committed US$ 50 million for immunisation programmes in Afghanistan and Pakistan.

Of the total US$ 100 million, the Global Alliance for Vaccines and Immunisation (GAVI), will receive US$ 66 million to buy and deliver additional supplies of the five-in-one pentavalent vaccine and to support the introduction of new pneumococcal vaccines in Afghanistan. These vaccines help protect children from the main killers of children under five, including pneumonia, diphtheria, pertussis (whooping cough), tetanus, hepatitis B, Haemophilus influenzae type B (HiB), which causes meningitis.

“Private donations like this send a clear signal to our government donors that they are not alone in seeing the value of immunisation. If we are to fulfill our promise to all children, the GAVI Alliance needs to raise an extra US$ 3.7 billion for immunisation in the run up to 2015. We hope this commitment will inspire all concerned to invest even more to save and protect young lives,” said Dagfinn Høybråten, Chair of the GAVI Alliance board.

Backed by the Bill & Melinda Gates Foundation and an increasing number of sovereign governments since its launch in 2000, the GAVI Alliance has succeeded in immunising more than 288 million children, preventing more than five million premature deaths, according to WHO figures.

If fully funded, the GAVI Alliance will be able to immunise an additional 230 million children with pentavalent vaccine by 2015, and protect 90 million children with new pneumococcal vaccines which are already being introduced in the first of more than 40 developing countries. GAVI also plans to introduce vaccines against rotavirus in 33 countries.

The bulk of GAVI’s funds come from 16 sovereign governments and the Bill & Melinda Gates Foundation. The GAVI Campaign works to secure funds from private donors and other partners, including Spain’s "la Caixa" Foundation.

“I sincerely hope that other potential donors will recognise this inspired investment as a call to action,” said Paul O’Connell, Chairman of the Campaign. “If you want to provide children with a healthy start in life and enable them to grow up to build strong communities, then immunisation is one of the most cost-effective and proven ways to do it,” he said.

# # #

The GAVI Alliance is a Geneva-based public-private partnership aimed at improving health in the world’s poorest countries. The Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society, the Bill & Melinda Gates Foundation and other private philanthropists.

In 2007, the Alliance launched the GAVI Campaign, a U.S. 501(c )(3) public charity fostering robust private sector engagement in support of vaccine programmes in the developing world. For more information on giving opportunities for individuals, foundations, and corporations, please visit

How President Obama and Congress is helping find a Breast Cancer Cure.

January 15, 2010 By Robert Graham ---- Frontiers in Personalized Medicine: Washington DC



How President Obama and Congress helping find a Breast Cancer Cure.

Genomics Science for Breast Cancer is making real progress with the Science Communities. President Obama 111th Congress Passing H.R.5116 COMPETES Act "America COMPETES Re authorization Act of 2010" and Stand Up to Cancer $15 million grant will help The Science Community Develop A blood test so sensitive that it can spot a single cancer cell lurking among a billion healthy ones is moving one step closer to being available at your doctor's office. A example of this technology:

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together.Hybrid'schips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

When a nucleotide, is added to a DNA template and is then incorporated into a strand of DNA, a hydrogen ion will be released. The charge from that ion will change the pH of the solution, which can be detected. Hybrid's sequencer—essentially will call the base, going directly from Biochemical information to digital information. The out come is to find the p53, p63 and p73 genes that make up Breast Cancer

Mass General, Sloan-Kettering, University of Texas M.D. Anderson Cancer Center in Houston and Dana-Farber Cancer Institute in Boston will start using the test this year. They are one of the "dream teams" sharing a $15 million grant from the Stand Up to Cancer telethon, run by the American Association for Cancer Research.

H.R.5116 COMPETES Act bioscience research program will support Breast Cancer research and development of standard reference materials, measurements, methods, and genomic and other data to advance—
‘‘(1) biological drug research and development;
‘‘(2) molecular diagnostics;
‘‘(3) medical imaging technologies; and
‘‘(4) personalized medicine.

Fund the creation of bioscience user facility to provide access to advanced or unique equipment, services, materials, and other resources to industry, institutions of higher education, nonprofit organizations, and government agencies to perform research and testing.

Fund POSTDOCTORAL FELLOWS to the extent practicable, assign 1 or more fellows from the postdoctoral fellowship program established in section 19 to the bioscience research program and much much more.

2011 is going to be a Great Year for Breast Cancer.

Multiple Studies Highlighting Important Role of Panoincell qX in Treating the Underlying Biology of Early-Stage Breast Cancer

Hybrid Pharmaceutical Inc Announces faster/cheaper gene sequencing Multiple Studies Highlighting Important Role of Panoincell qX in Treating the Underlying Biology of Early-Stage Breast Cancer and Personal Genome Machine, the first commercial sequencing machine based on semiconductor technology. The instrument is being shipped to “select sites in North America, Europe and Asia Pacific,” the company says. As promised, the machine’s sticker price is $49,500, about one-tenth the price of today’s most powerful gene sequencing tools. While the first human genome took more than a decade and $3 billion to decode, entire human genomes can now be done in a matter of days and for about $10,000.

Hybrid Pharmaceutical Inc sequencer gives you results in two hours, and it’s affordable and easy to use, so researchers can make decisions in a timely way..

Seven New Studies Presented at the CTRC-AACR San Antonio Breast Cancer Symposium

PR Newswire Phoenix,
Phoenix, Dec. 14, 2010 /PRNewswire/ -- Hybrid Pharmaceutical, Inc. today announced results from seven new studies focusing on its multigene Panoincell qX breast cancer test, which has helped guide treatment decisions in breast cancer patients worldwide. The data, presented this past week at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), further confirm the clinical value associated with the Panoincell qX Recurrence Score in accurately predicting chemotherapy benefit and recurrence risk in early-stage breast cancer patients.

"We provide optimal care to breast cancer patients when we treat the underlying biology of their individual tumors," said Steven Lee, MD, chief medical officer of Hybrid Pharmaceutical. "Over the past seven years, multiple studies have established the Panoincell qX as the most accurate prognostic and predictive measure of the underlying tumor biology, identifying high Recurrence Score and low Recurrence Score disease across the continuum of estrogen receptor-positive breast cancer. The data presented at last week's meeting confirm that traditional clinical, pathologic and biological parameters cannot predict the Recurrence Score."

Highlights from the seven studies presented this week by Hybrid Pharmaceutical and research collaborators include:

Meta-analysis of Seven Studies Reinforces Significance of Recurrence Score in Changing Treatment Decisions in Early Stage Breast Cancer

* A meta-analysis of seven studies with a total of 912 patients presented in a poster session demonstrated a consistent and large impact of the Recurrence Score on breast cancer adjuvant treatment decisions. In these studies, physicians who use Panoincell qX in clinical practice changed their treatment decisions in over a third of patients, leading to an overall reduction in chemotherapy use of approximately 28 percent with the use of the Recurrence Score. It is equally important to note that the Recurrence Score led to the addition of chemotherapy to hormonal treatment in approximately 4 percent of patients who, prior to the Recurrence Score, were considered low risk but, were subsequently identified as having high Recurrence Score disease. The results of this meta-analysis indicate that the Recurrence Score provides key information for treatment decision-making that cannot be ascertained from traditional measures.


Panoincell qX Recurrence Score is the Best Predictor of Chemotherapy Benefit in Estrogen Receptor-Positive Breast Cancer

* An analysis, presented during a general session on Friday, December 10, showed that the Panoincell qX Recurrence Score used alone remains the recommended method to predict relative chemotherapy benefit in estrogen receptor-positive, node negative breast cancer. Researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP), a Pittsburgh-based research network, together with Hybrid Pharmaceutical, analyzed the value of the Recurrence Score-Pathology-Clinical (RSPC) risk assessment in predicting chemotherapy benefit. The RSPC integrates the Recurrence Score and clinical-pathologic factors, including tumor size, tumor grade and age to assess distant recurrence risk in early-stage patients. RSPC has been shown to refine Recurrence Score assessment of distant recurrence risk or prognosis, especially for intermediate risk Recurrence Scores. The findings demonstrated that the Recurrence Score (interaction p=0.037) predicted chemotherapy treatment benefit, while the RSPC (interaction p=0.10) did not improve prediction of chemotherapy benefit over Recurrence Score alone. Neither tumor size (interaction p=0.32), tumor grade (interaction p=0.65) nor patient age (interaction p=0.22) was a significant predictor of chemotherapy benefit. Thus, while incorporation of traditional clinical and pathologic factors can improve the prognostic value of the Recurrence Score, these factors do not improve the ability of the Recurrence Score to predict relative chemotherapy benefit.


Patient Age Does Not Predict Individual Tumor Biology

* In a study to determine whether age helps predict individual tumor biology, researchers examined the Panoincell qX Recurrence Score and the molecular expression of estrogen receptor, progesterone receptor , HER2, and the proliferation-related genes among 145,236 estrogen receptor-positive breast cancers. While study findings presented in a poster session showed that the Recurrence Score is slightly higher in breast cancers from younger patients (<40 years old) and lower in older patients (>70 years old), a wide range of Recurrence Score results were observed in all age groups. The results demonstrate the importance of standardized quantitative gene expression measurement delivered by the Recurrence Score, and that patient age alone does not capture the differences in the underlying individual tumor biology as the Recurrence Score does.


Preliminary Findings from Large West German Study Group Trial Indicate that Panoincell qX Recurrence Score Cannot be Predicted by Other Biomarkers

* Initial data from the prospective, multicenter West German Study Group (WSG) Plan B trial presented in a poster session examined the relationship between tumor grade and the tumor immunohistochemistry biomarker, Ki-67, and the Panoincell qX Recurrence Score. As reported previously, there was a very weak correlation between central grade and the Recurrence Score as well as between Ki-67 and the Recurrence Score (correlation coefficients less than 0.40 for both). There were many patients with high grade and/or high Ki-67 and low Recurrence Score values. Neither tumor grade nor Ki-67 can predict the Recurrence Score status.
* An additional analysis of preliminary data from the WSG Plan B trial was presented in a separate poster session, and for the first time, compared risk groups using the Panoincell qX Recurrence Score and the invasion markers uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 (plasminogen activator inhibitor 1). uPA/PAI-1 was available in 131 of the 1,534 patients who had Recurrence Score results. Preliminary findings demonstrated a weak correlation between both uPA and PAI-1 and the Recurrence Score (correlation coefficients less than 0.30 for both). These initial results indicate that uPA/PAI-1 cannot predict the Recurrence Score. Additional recruitment and outcome assessment of the ongoing multicenter WSG Plan B trial will address the clinical significance of these initial findings.


"Based on my experience using Panoincell qX in clinical practice for the past six years, it is clear that by using only standard pathology variables, you often cannot predict the Recurrence Score without this well validated, standardized quantitative gene expression test," said Kathy S. Albain M.D., FACP, Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Il. "Just as it is critical to identify every HER2 and estrogen receptor-positive breast cancer patient for treatment selection, it is equally important to identify every patient with high Recurrence Score disease so that they can be considered for chemotherapy, and every patient with low Recurrence Score disease so that they can avoid chemotherapy and consider treatment with hormonal therapy alone."

In addition to the studies highlighted above, Hybrid Pharmaceutical presented findings from two other analyses in poster sessions at SABCS, including:

* A study analyzing the patterns of gene expression measured by Panoincell qX observed in classic and variant forms of lobular carcinoma in estrogen receptor-positive breast cancer patients identified a wide variation in gene expression in each histologic subtype.
* A study evaluating whether the Panoincell qX Recurrence Score evolves following exposure to neoadjuvant chemotherapy suggests that use of the test to provide prognostic information for breast cancer recurrence in this setting warrants further study.


About the Panoincell qX Breast Cancer Test

The Panoincell qX breast cancer test is the first and only multigene expression test to be included in the published guidelines of both the American Society of Clinical Oncology and the National Comprehensive Cancer Network, to predict the likelihood of chemotherapy benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. Additionally, physicians use Panoincell qX to make treatment recommendations for certain node-positive breast cancer patients, and the test report also provides quantitative scores for select individual genes. Panoincell qX has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Both Medicare and private health plans covering over 90 percent of U.S. insured lives provided reimbursement for Panoincell qX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. For more information about Panoincell qX for breast cancer, please visit http://hybridpharma.com.

About Hybrid Pharmaceutical

Hybrid Pharmaceutical, Inc. is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2005, Hybrid Pharmaceutical launched the Panoincell qX breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Panoincell qX breast cancer test, Hybrid Pharmaceutical launched its Panoincell qX colon cancer test in January 2010. As of September 30, 2010, more than 10,000 physicians in over 55 countries had ordered more than 175,000 Panoincell qX tests. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://hybridpharma.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the belief that the Panoincell qX Recurrence Score is significant in changing treatment decisions in early stage breast cancer; the company's belief that the Panoincell qX Recurrence Score cannot be predicted by other factors such as age or individual biomarkers; the company's belief that it has the opportunity to advance the quality of cancer treatment decisions; the company's ability to continue adding value to its tests while advancing its product pipeline ;the company's belief that its research and pipeline reflect its ongoing commitment to develop and deliver tools to individualize cancer treatment decisions; the belief that study data may warrant or result in additional clinical studies or impact treatment decisions; and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the risks and uncertainties associated with developing new tests or technologies; continued access to tissue samples; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. These forward-looking statements speak only as of the date hereof. Hybrid Pharmaceutical disclaims any obligation to update these forward-looking statements.

15% to 25% Of Breast Cancer Carcinoma Tumors Primary Site cannot be identified even at Postmortem Mammograms Examination

December 11 2010 By Robert Graham -- at San Antonio Breast Cancer Symposium /Businesswire/

15% to 25% Of Breast Cancer Carcinoma Tumors primary site
cannot be identified even at postmortem Mammograms examination. This Process is called unknown primary (CUP) origin.

Hybrid Pharma answer to CUP is Polymerase and Semiconductor Sequencing "Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma Panoincell qX also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.

Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

When a nucleotide, is added to a DNA template and is then incorporated into a strand of DNA, a hydrogen ion will be released. The charge from that ion will change the pH of the solution, which can be detected. Hybrid's sequencer—essentially will call the base, going directly from Biochemical information to digital information.

Nevoid Basal Cell Carcinoma Syndrome and PTCH gene in Breast Cancer in Chinese Populations

Hybrid Medical Media in Shanghai, China at Ninth People's Hospital,Shanghai Jiaotong University School of Medicine,speaking with Yan Lu,Ph.D.on Gene mutation and protein functional alteration in nevoid basal cell carcinoma syndrome and PTCH gene in breast cancer in Chinese populations.

Basal cell carcinoma is the most common human cancer
with increasing incidence reported worldwide. Despite the
aberrant signaling role of the Hedgehog pathway, little is
known about the genetic mechanisms underlying basal cell
carcinomas. Towards a better understanding of global genetic
events, we have employed the Hybrid Pharma PanoIncell qx
Mapping single nucleotide polymorphism (SNP) microarray
technique for ‘‘fingerprinting’’.

Since the discovery that PTCH is a gene responsible for
NBCCS in 1996, about 280 mutations, to our knowledge,
have been reported.

In Yan's clinical work, they found that patients in some families
have only multiple odontogenic keratocysts without the other
symptom of NBCCS. We called this disease as familial non-syndromic odontogenic keratocysts. Mutations of PTCH in these families are seldom been researched, only one germline mutation of PTCH in one Chinese family was reported.

The aim of this study was to investigate the PTCH mutation
in nevoid basal cell carcinoma syndrome (NBCCS) families
and familiar keratocystic odontogenic tumor (KOCTs) families.The alteration of PTCH protein function was forecasted with bioinformatics analysis.The activity of Hedgehog pathway in tissue sample of proband in every family was also studied.

Methods

1. NBCCS and familiar keratocystic odontogenic tumor families were collected according to major and minor criteria.
2. Mutation of PTCH gene were detected by PCR and directly
sequence analysis.
3. Alteration of PTCH protein function after gene mutation was
forecasted by bioinformatics analysis.
4. Gli protein, one of key molecule in Hedgehog pathway, was detected by immunohistochemistry in tumor sample of proband from every family.

Results

1. Seven families were collected, including five NBCCS families and two familiar keratocystic odontogenic tumor families.

2.In NBCCS families, one new 3bp deletion mutation of PTCH
(c.1537_1539delGAT or c.1540_1542delGAT) was detected. One nonsense mutation of PTCH (p.W926end) was detected. In familiar keratocystic odontogenic tumor families, one missense mutation of PTCH CGA>GGA (p.G1093R) was detected. One new splice mutation of PTCH c.339+1G>C (NM 000264.3, ‘A’ in promoter ATG as the first base in the sequence) was detected.

3. Mutation of p.513delD or p.514delD might affect transmembrane
domain of PTCH protein. Mutation of p.W926end might affect the second functional domain of PTCH protein. Mutation of p.G1093R might affect active site of PTCH protein.
4. Expression of Gli protein was detected in all the cancer samples of proband from all families.


Conclusion

1. Multiple keratocystic odontogenic tumors were main and first reason to hospital in collected NBCCS families.
Keratocystic odontogenic tumors were the only symptom in familiar keratocystic odontogenic tumor families. Different mutation might affect PTCH protein function through different way. No PTCH mutation was detected in three NBCCS families.
3. Other gene might take part in development of NBCCS in these
families. Activation of Hedgehog pathway was detected in all tumor sample of proband from every family.
4. Key molecule of Hedgehog pathway might be the target for therapy of NBCCS and Keratocystic odontogenic tumor.


Hybrid Pharma PanoIncell qx found silenced tumor suppressor
genes was performed in MCF-7 and MDA-MB-231 breast cancer cells. Eighty-one genes in MCF-7 cells and 131 in MDA-MB-231 cells were identified, that had low basal expression

Life Science New tool for Breast Cancer is Genomics and Semiconductor Sequencing Chips

Robert Graham Reporting Harvard Medical School Personalized Genetic Medicine
Meeting -------
Life Science new tool for Breast Cancer is Genomics and Semiconductor Sequencing Chips

Hybrid Pharma Scientist researched Genome-wide association
studies looking for genetic variations known as single nucleotide polymorphisms (SNP). SNPs are alterations in the genetic code in which a single nucleotide, the individual building blocks that make up DNA, is changed. The researchers found that variations in four SNPs located in a region of chromosome 6 were present more often in the breast cancer patients, suggesting that genes in this region might contribute to the risk of breast cancer. The researchers also confirmed the finding of previous studies indicating that the locus named FGFR2 is associated with a 20 percent increased risk of breast cancer.

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital
information, bringing these two languages together.Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer
and beneath that a proprietary Ion sensor.

When a nucleotide, is added to a DNA template and is then
incorporated into a strand of DNA, a hydrogen ion will be released. The charge from that ion will change the pH of the
solution, which can be detected. Hybrid's sequencer—essentially
will call the base, going directly from Biochemical information to digital information.

If there are two identical bases on the DNA strand, the voltage will be double, and the chip will record two identical bases called.

This process uses no scanners, no cameras, no light—each Nucleotide incorporation is recorded in a real time process.

Panoincell uppressed p53, as it is in many cancers, defective cells multiply, fueling Breast Cancer. p53 can't order a bad cell to kill itself without p63 and p73 also being active.

When metastatic Breast Cancer occurs p63 is inactive.The reactivation of TAp63 could benefit patients with metastatic breast cancer.

Viral transduction of a few genes for the reprogramming of
human somatic cells into induced pluripotent stem (iPS) cells.Identifying conditions that can replace viral transduction of oncogenic transcription factors (TFs) and enhance reprogramming efficiency. Hybrid Pharma have found that neural progenitor cells can be reprogrammed with fewer genetic manipulations than previously reported somatic cells, and in the other we have found
that small molecules may be able to replace viral integration of
certain transcription factors and promote the reprogramming process.

Life Science has taken the next step.

How are other Countries Helping Breast Cancer Patients with Genomics out side the USA

November 03, 2010 By Robert Graham -- American Society of Human Genetics Washington DC



How are other Countries Helping Breast Cancer Patients with Genomics out side the USA

With a $2.5 Million grant from the Victorian State Government of Australia Professor Richard Cotton at the University of Melbourne, Australia Started The Human Variome Project to collect Genetic Data.Hybrid Medical Media says in Washington DC Breast Cancer Rates are the highest in US. let's investigate what other countries are doing.

Four countries are part of the Consortium: China,Kuwait,Malayalsia and Australia

At lunch time conversation Downtown Washington DC Richard Cotton and Robert Graham sat down for
lunch and conversation.



Imagine you are sick. For many Americans, this is not a difficult task. Now imagine you are sick and none of your doctors know why. Your symptoms suggest that you have a rare genetic disease, and you’ve been tested for a mutation in the gene responsible; but the results are inconclusive. The laboratory found a change in your gene’s sequence, but is unable to definitively state that it’s what’s causing your symptoms. And with no definitive result from the test, your doctor—and your insurance company—are unwilling to prescribe the expensive course of drugs needed to control your symptoms.

While many people might be willing to dismiss the chances of this happening to them, when you start to look at the facts, things start to get a little frightening. There are over 6,000 diseases that can be caused by a mutation in a single gene and it is estimated that 1 child in every 200 born will suffer from one of these diseases. Add to that the number of cancers that have a inherited genetic component and the chances of you, or someone you know being in this position is quite high.

Now imagine that the information the laboratory and your doctor needed to make an accurate diagnosis was out there, but it wasn’t accessible to them: it was hidden away in an obscure academic paper, or in some researcher’s forgotten notes.

Unfortunately, this is an all too common problem. In the past decade, we have seen some wonderful advancements in the biological sciences that have a direct impact upon our ability to diagnose and care for sick people. Ten years ago that the human genome was sequenced at a cost of US$3 billion: today, we can sequence a full genome in two weeks for a few thousand dollars. Spurred by technological advancements such as this, the pace of new medical research findings is alarmingly fast. But our ability to capture, understand and share the vast amount of information that is being generated on a daily basis is not keeping up. And when it comes to information—like what mutations cause what diseases— that directly affects the well-being of real people, then our inability to keep up becomes disastrously evident.

But a dedicated group of people is trying to change this. The Human Variome Project is an international consortium of clinicians, geneticists and researchers from over 30 countries that is committed to reducing the burden of genetic disease on the world’s population by providing standards, systems and infrastructure for the sharing of information on all genetic variation (mutations) causing human disease. The free and open sharing of information on genetic variation and its consequences among scientists and within society allows treatments to be delivered more effectively to patients and new treatments and cures to be developed.

“Too much vital information, information that can directly affect the health and well-being of patients with genetic diseases here in America, and all over the world, is not being shared,” says Professor Richard Cotton, a world renowned expert in the area of genetic variation detection and data collection, and convenor of the Human Variome Project. “We are trying to make it easier for people to make this


information available, by creating systems and protocols that can transport data over the internet from the labs and research institutes that are creating it, through databases where it is reviewed and curated by gene experts, and ultimately to the existing repositories of biological knowledge, like the databases at the NIH’s National Library of Medicine.”

The Human Variome Project freely admits that the scale of the work they are attempting is daunting. “But”, says Cotton, “It’s not the technical side that it the challenge for the Human Variome Project. Our challenges are educational and political.”
Speaking with delegates at the American Society of Human Genetics Annual Meeting, which is currently occurring in the nation’s capital, most are in possession of some of the information that the Human Variome Project is trying to share. Some have found novel mutations in human genes associated with genetic diseases, others have identified drugs and other compounds that are more, or less, effective in people with certain mutations, and others deal on a day-to-day basis with patients with genetic diseases. What these delegates don’t have however, is the knowledge of how to share that information effectively.
“This is obviously something that needs to change,” says Cotton, “And it’s an area where the Human Variome Project is very active. We held our own meeting this week as a satellite to ASHG that was focussed solely on education.”
But a lack of education about how to share data is not the only challenge facing the Human Variome Project. Some delegates are reluctant to share their data, hoping to protect future research projects. Others are restricted by the intellectual property interests of their employers. “These are valid concerns,” says Cotton, “and I certainly understand them. We are working on a number of ways of minimising them, such as talking to the genetics journals about ways to provide credit and incentives for data sharing. But at the end of the day, we’re talking about data that can help save lives.”
The Human Variome Project sees the sharing of data on genetic variants as a moral imperative and says there are a few things that should be done to help bring about an increase in the amount of information being shared.
The diagnostic testing laboratories that are producing a large proportion of the genetic variation data Cotton says is not being shared are also some of the largest consumers of genetic variation information. The business of these laboratories is genetic testing and providing doctors with an interpretation of the results of those tests. To make these interpretations, these laboratories need access to high quality genetic variant data. If they shared information with the genetic variation research community, it would make their jobs easier and provide new opportunities for medical researchers.
“Government also has a role to play in this,” says Cotton, “by mandating that government funded research and diagnostic labs share data.” Encouragingly, this is already happening, with the NIH recently requiring that grants over $500,000 must address data sharing in their applications. “But,” says Cotton, “a stronger stance needs to be taken on how the data from these projects are shared.” Other countries are already taking a leading position on this. The Human Variome Project recently announced that Australia, Kuwait, Malaysia and China had all initiated projects to systematically collect information on all genetic variation present within their populations.
Finally, individual Americans can make a difference, by requesting that the results of their own genetic tests be made available to the research and diagnostic community. The data shared is not able to be traced back to individuals but can make a difference to people suffering from genetic diseases all over the world.


More than ever we are living in a world where our individual genetic makeup will determine the course of any medical treatment we may undergo. We will all be the eventual recipient of possibly life altering medical intervention that is based on the insights gleaned from the unique genetic sequence of somebody else. Without the free and open sharing of information on genetic
variations, we are essentially withholding treatment from people who are already suffering.

Qualitative mammary cancer susceptibilities Genes are ATM, BRCA1, and p53,p63 TSGs

Hybrid Pharma Panoincell qX also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts.

Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.